Suppr超能文献

头孢雷特在接受血液透析的终末期肾病患者中的药代动力学。

Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.

作者信息

Hess J R, Berman S J, Boughton W H, Sugihara J G, Musgrave J E, Wong E G, Siemsen A M

出版信息

Antimicrob Agents Chemother. 1980 Feb;17(2):251-3. doi: 10.1128/AAC.17.2.251.

Abstract

The pharmacokinetics of ceforanide were evaluated in 11 patients with end stage renal disease (creatinine clearance less than 5 ml/min). A single intravenous dose of 750 mg/m2 produced peak plasma concentrations of 123 +/- 29 microgram/ml. The plasma half-life (T 1/2) of the drug was 19.1 +/- 2.5 h. A 5.5 h hemodialysis session removed 53% of the drug and reduced the T 1/2 to 5 +/- 0.7 h. Plasma concentrations greater than 10 microgram/m2 were maintained without adverse effects with a 1.5-g/m2 dose administered three times a week for 2 weeks.

摘要

对11例终末期肾病患者(肌酐清除率低于5 ml/min)进行了头孢雷特的药代动力学评估。静脉单次给药750 mg/m²后,血浆峰浓度为123±29微克/毫升。该药的血浆半衰期(T½)为19.1±2.5小时。5.5小时的血液透析疗程清除了53%的药物,并将T½缩短至5±0.7小时。每周给药3次,每次剂量1.5 g/m²,持续2周,可维持血浆浓度大于10微克/平方米,且无不良反应。

相似文献

2
Ceforanide kinetics in renal insufficiency.头孢雷特在肾功能不全患者中的动力学
Clin Pharmacol Ther. 1981 Oct;30(4):468-74. doi: 10.1038/clpt.1981.190.
3
Pharmacokinetics of ceforanide.头孢雷特的药代动力学。
Antimicrob Agents Chemother. 1982 Feb;21(2):323-6. doi: 10.1128/AAC.21.2.323.
6
Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.
J Clin Pharmacol. 1979 Jul;19(7):366-77. doi: 10.1002/j.1552-4604.1979.tb02493.x.

本文引用的文献

6
Ceforanide: in vitro and clinical evaluation.头孢雷特:体外及临床评估
Antimicrob Agents Chemother. 1979 Sep;16(3):386-91. doi: 10.1128/AAC.16.3.386.
8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验